Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylphenidate + guanfacine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate + guanfacine is a combination therapy used primarily in the treatment of attention-deficit/hyperactivity disorder (ADHD), especially in children who have an inadequate response to monotherapy. Methylphenidate is a central nervous system stimulant that inhibits the reuptake of norepinephrine and dopamine, increasing their concentrations in the synaptic cleft. Guanfacine is an alpha-2A adrenergic receptor agonist that acts on prefrontal cortical receptors to enhance executive function and reduce hyperactivity and impulsivity. The combination may provide greater improvements in ADHD symptoms than either drug alone, particularly for visuo-attentional deficits and working memory performance[3][4][8]. However, combined use can affect cardiac rhythm and requires monitoring for potential side effects such as irregular heartbeat or changes in blood pressure[1].
- Brand names
- IntunivConcerta
- Other names
- d-methylphenidate + guanfacinemethylphenidate hydrochloride + guanfacine hydrochloride
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)ADRA2A (α2A)
Beyond the preview
Go deeper on Methylphenidate + guanfacine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Methylphenidate + guanfacine.